Advanced RCC Can Still Respond to Nivolumab After Initial Progression
A subset of patients with advanced renal cell carcinoma experienced a reduction in tumor size after undergoing postprogression treatment with nivolumab.
Cancer-Related End-Stage Renal Disease Incidence Increasing
From 1983 to 2007, the incidence of renal-malignancy end-stage renal disease has greatly increased, according to the results of a study published.
Adiponectin Signaling May Explain “Obesity Paradox” of RCC
BMI was inversely correlated with serum adiponectin levels in RCC, and low BMI and high adiponectin might be associated with disease aggressiveness and survival in patients with the disease.
Adjuvant TKI Use in High-Risk Clear Cell RCC Not Effective
Updated results of the ASSURE trial showed that adjuvant sunitinib or sorafenib did not improve disease-free survival among high-risk patients with renal cell carcinoma.
Vorinostat Plus Bevacizumab Had Activity in Previously Treated RCC
Using the HDAC inhibitor vorinostat plus the VEGF inhibitor bevacizumab resulted in clinical activity in patients with clear cell renal cell carcinoma.
Does Active Surveillance Benefit Patients With Metastatic RCC?
Active surveillance prior to initiating targeted therapy might benefit patients with metastatic renal cell carcinoma, since it delays therapy and toxicities.
Computer-Aided Evaluation of Tumor Response Could Benefit RCC Patients
Computer-assisted tumor objective response evaluations for patients with metastatic renal cell carcinoma can save time and reduce errors.
Kidney Cancer Highlights of 2016
This slideshow takes a look at some of the top kidney cancer news of 2016, including FDA approvals, survival disparities, surgical approaches, and more.
Oncology Drug Snapshot: Axitinib (Inlyta)
This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
By clicking Accept, you agree to become a member of the UBM Medica Community.